Does Network Health Cover Viagra?

What Is Network Health and How Does Its Formulary Work?

Network Health is a Wisconsin-based regional health insurer offering commercial, Medicare Advantage, and Marketplace plans primarily across northeastern and central Wisconsin. Like all U.S. health plans, it publishes an annual formulary, a tiered drug list that determines what you pay out of pocket. Drugs placed at higher tiers carry higher cost-sharing, and drugs not on the formulary at all must be obtained through an exception process or paid for entirely out of pocket.

Formularies are reset each plan year, typically January 1. A drug covered in 2024 may be excluded, tier-changed, or subject to new utilization management rules in 2025. The FDA's drug approval process and a plan's formulary decisions are legally separate. FDA approval of sildenafil for erectile dysfunction in March 1998 [1] does not obligate any insurer to cover it.

Pharmacy benefit managers (PBMs) negotiate rebates with manufacturers, and those negotiations directly shape formulary placement. Because generic sildenafil manufacturers offer smaller rebates than branded drugs, generic sildenafil may still land at a mid-level tier rather than the preferred generic tier, which surprises many patients.

To find your exact current-year Network Health formulary, log in at the Network Health member portal, search your plan name on the Wisconsin Office of the Commissioner of Insurance website, or call the member services number printed on your insurance card. The FDA's drug database confirms approved indications and formulations for sildenafil [2].

Does Network Health Cover Brand-Name Viagra Specifically?

Brand-name Viagra is rarely covered by commercial plans since generic sildenafil became widely available in December 2017. Most Network Health commercial plans either exclude brand Viagra outright or place it at a non-preferred specialty tier with cost-sharing that effectively makes it unaffordable compared to the generic.

The generic equivalent, sildenafil citrate, contains the identical active molecule at the same approved doses (25 mg, 50 mg, 100 mg) and must meet FDA bioequivalence standards, meaning it delivers the same amount of drug to the bloodstream within the same timeframe as the brand [3]. Clinically, the switch from brand to generic sildenafil produces no meaningful difference in efficacy or safety for most patients.

If your prescriber writes "brand medically necessary" on the prescription and your plan allows brand-medically-necessary exceptions, you can request a coverage exception. These exceptions require documented clinical justification and are rarely granted for sildenafil given the strong bioequivalence data.

The American Urological Association's 2018 guideline on erectile dysfunction states that "PDE5 inhibitors are recommended as a first-line therapy for erectile dysfunction" [4]. That guideline endorses the class, not a specific brand, which gives plans latitude to require generic substitution.

Prior Authorization Requirements for Sildenafil Under Network Health Plans

Prior authorization (PA) is the most common hurdle men face when trying to fill sildenafil for erectile dysfunction. Even when generic sildenafil appears on a plan's formulary, Network Health, like most commercial insurers, typically requires PA before the first fill.

Standard PA criteria for sildenafil ED coverage generally include: a confirmed diagnosis of erectile dysfunction (ICD-10-CM code N52.x), documentation that the prescriber has assessed cardiovascular risk (because PDE5 inhibitors are contraindicated with nitrates [5]), and sometimes evidence that the patient has tried or been counseled on lifestyle modification given that obesity, smoking, and physical inactivity are modifiable risk factors for ED [6].

Your prescriber's office submits the PA request. If denied, you have the right to appeal. Under the No Surprises Act and existing state insurance law in Wisconsin, plans must provide a written denial reason and an appeals pathway. A clinical peer-to-peer review, where your physician speaks directly with the plan's medical director, resolves many PA denials at the first appeal.

Approvals, when granted, typically come with a quantity limit of 6 tablets per 30-day supply, consistent with the labeled dosing of one tablet per 24-hour period [7].

How the Pulmonary Arterial Hypertension Indication Changes Coverage

Sildenafil 20 mg tablets marketed as Revatio carry FDA approval for pulmonary arterial hypertension (PAH), a life-threatening condition distinct from erectile dysfunction [8]. Coverage rules for this indication are substantially different.

PAH is not classified as a lifestyle or sexual function condition. Because it carries significant morbidity and mortality, most health plans, including Network Health's commercial and Medicare Advantage products, are more willing to cover sildenafil 20 mg under the PAH indication than the ED indication. PA is still required, but the clinical threshold for approval is lower since the alternative is progressive right heart failure.

If you have PAH and your physician prescribes sildenafil, the prescription should specify the PAH diagnosis and the 20 mg dose three times daily (the FDA-approved PAH dosing regimen). Using the 50 mg or 100 mg ED-labeled tablets for PAH is off-label and may trigger a coverage denial even if Revatio is approved [9].

The FDA's Revatio prescribing information, publicly available through the FDA drug database, outlines the approved PAH indication and contraindications in detail [10].

Generic Sildenafil vs. Other PDE5 Inhibitors on Network Health Formularies

PDE5 inhibitors as a class include sildenafil, tadalafil (Cialis/generic), vardenafil (Levitra/generic), and avanafil (Stendra). Network Health formularies often cover at least one or two generics in this class, and the preferred agent varies by plan year based on PBM negotiations.

Tadalafil has a 36-hour half-life compared to sildenafil's 4-to-6-hour half-life, which some patients prefer because it removes the need to time the dose close to sexual activity [11]. Generic tadalafil is also available at very low cash prices. A published pharmacoeconomic analysis in the Journal of Sexual Medicine found that once-daily low-dose tadalafil (5 mg) improved erectile function scores on the IIEF-5 scale by a mean of 6.8 points versus placebo over 12 weeks [12].

Avanafil (Stendra) has the fastest onset at approximately 15-30 minutes and carries a lower rate of the visual color-tinge side effect associated with sildenafil, because it has higher selectivity for PDE5 over PDE6 [13]. Avanafil remains brand-only in the United States as of early 2025, so it typically sits at a high formulary tier or is excluded.

Vardenafil generic became available in 2018 and is structurally similar to sildenafil with a similar duration of action. Orodispersible vardenafil (Staxyn) dissolves under the tongue and may be preferred by patients who have difficulty swallowing tablets.

If your Network Health plan excludes sildenafil, ask your prescriber whether a different PDE5 inhibitor on the preferred formulary tier would be clinically appropriate for you. A step-therapy requirement, meaning you must try a preferred drug before a non-preferred drug is covered, is common [14].

Medicare Part D and Viagra: A Statutory Exclusion

If you are on a Network Health Medicare Advantage plan, a federal statute directly governs this issue. Under 42 U.S.C. § 1395w-102(e)(2)(A), Part D plans are prohibited from covering drugs used exclusively for the treatment of sexual or erectile dysfunction unless the drug is used for a different medically accepted indication [15].

This is not a Network Health policy choice. It is a congressional restriction. No Medicare Part D plan legally covers sildenafil 100 mg prescribed for erectile dysfunction. The only exception is sildenafil 20 mg prescribed for PAH, which falls under a different medically accepted indication and may be covered.

The Centers for Medicare and Medicaid Services (CMS) has published guidance confirming this exclusion [16]. Patients who need sildenafil for ED while on Medicare must pay out of pocket. At major pharmacy chains, generic sildenafil 50 mg can be obtained for under $1 per tablet using discount programs such as GoodRx, making the out-of-pocket cost manageable for many patients even without insurance coverage.

ACA Marketplace Plans and State Mandates

Network Health offers Marketplace (ACA) plans in Wisconsin. The Affordable Care Act established ten essential health benefits but did not include erectile dysfunction drugs in that list [17]. States may add mandates on top of the federal baseline, but Wisconsin has not enacted a mandate requiring coverage of PDE5 inhibitors for erectile dysfunction as of the 2025 plan year.

This means ACA plan coverage of sildenafil on Network Health Marketplace products is discretionary. Network Health may include generic sildenafil on its Marketplace formulary as a voluntary benefit, or it may exclude it. Check your specific plan's Evidence of Coverage (EOC) document, available through the Network Health member portal or HealthCare.gov.

The ACA does require that any formulary exclusion be subject to an exception process for medically necessary drugs. If your physician documents that sildenafil is medically necessary for a covered condition (for example, PAH or a documented comorbidity where other treatments are contraindicated), you have grounds for a formulary exception request [18].

How to Request a Coverage Exception or Appeal a Denial

A denial is not the end of the road. Federal law under the Employee Retirement Income Security Act (ERISA) and state insurance law both provide structured appeals rights.

Step one: request an internal appeal. Your plan must respond within 72 hours for urgent requests and 30 days for standard prescription drug appeals under CMS regulations. Submit your prescriber's clinical notes, the diagnosis code, and any peer-reviewed literature supporting the treatment.

Step two: if the internal appeal fails, request an external review. In Wisconsin, the Office of the Commissioner of Insurance oversees external reviews for state-regulated plans. For ERISA-governed employer plans, external review is conducted by an independent review organization (IRO) designated by the plan.

Step three: ask your prescriber about manufacturer programs. Pfizer has historically offered patient assistance for brand Viagra through its patient assistance program, though eligibility requirements change annually.

The HealthRX clinical team recommends the following approach for patients whose Network Health plan denies sildenafil coverage:

1. Confirm the denial reason in writing (formulary exclusion vs. PA denial vs. step therapy).
2. If PA denial: have your prescriber submit clinical documentation including the N52.x diagnosis, cardiovascular clearance, and IIEF-5 score if available.
3. If step therapy: ask whether tadalafil, the plan's preferred PDE5 inhibitor, is an acceptable clinical substitute for you.
4. If formulary exclusion: request a formulary exception citing medical necessity, then proceed to external review if denied.
5. If all insured paths fail: price generic sildenafil at GoodRx or Cost Plus Drugs before assuming unaffordability. As of January 2025, generic sildenafil 50 mg 30-tablet supply is available for under $25 at many U.S. pharmacies through discount programs.

The Clinical Case for Treating Erectile Dysfunction Regardless of Coverage

Erectile dysfunction affects an estimated 30 million men in the United States [19]. It is not only a quality-of-life issue. ED is an independent predictor of future cardiovascular events. A 2018 meta-analysis published in the Journal of the American Heart Association (N=154,794 across 25 studies) found that men with ED had a 43% higher risk of cardiovascular disease compared with men without ED (relative risk 1.43 to 95% CI 1.27-1.61, P<0.001) [20].

The Massachusetts Male Aging Study, one of the most cited longitudinal studies on ED, found a combined prevalence of minimal, moderate, and complete ED of 52% in men aged 40 to 70 [21]. That prevalence rises steeply with age, comorbid diabetes, hypertension, and smoking.

The clinical point here is that when insurers create barriers to PDE5 inhibitor access, some patients defer treatment altogether. Deferred treatment for ED may mean missing an opportunity to identify and address underlying cardiovascular risk factors. The American Heart Association recommends that men presenting with ED be evaluated for cardiovascular disease risk factors [22].

Sildenafil's safety profile is well-established. The key Phase III trials submitted to the FDA showed that sildenafil significantly improved erectile function versus placebo across all severity levels, with the most common adverse effects being headache (16%), flushing (10%), and dyspepsia (7%), and with serious adverse events no more frequent than placebo in the absence of nitrate use [23]. The FDA approved sildenafil on March 27, 1998, making it one of the longest-safety-tracked oral ED treatments available.

Telehealth and Compounded Sildenafil as Coverage Alternatives

Telehealth platforms that prescribe sildenafil have grown substantially since 2019. Hims, Roman, and similar services sell generic sildenafil directly to consumers after an online medical consultation, at prices that undercut many insurance copays. These are not insurance-covered services, but they bypass the PA and formulary hurdle entirely.

Compounded sildenafil, typically from a 503A or 503B compounding pharmacy, is another option some prescribers offer. The FDA does not review compounded drugs for efficacy or consistency [24]. Patients should ask their prescriber whether the compounding pharmacy is accredited by the Pharmacy Compounding Accreditation Board (PCAB) and whether the formulation has been tested for potency.

Injectable alprostadil (Caverject) and urethral suppository alprostadil (MUSE) are non-oral options covered under the medical benefit (not pharmacy benefit) of most plans. Coverage rules for medical-benefit drugs are separate from pharmacy formulary rules. If your pharmacy benefit excludes sildenafil, your medical benefit might still cover an office-administered or self-injected ED treatment [25].

Low-intensity shockwave therapy (LiSWT) is an emerging non-pharmacological option. A 2021 meta-analysis in the Journal of Urology (N=1,195, 14 RCTs) found that LiSWT significantly improved IIEF scores versus sham (weighted mean difference 2.00 to 95% CI 1.37-2.63, P<0.001), with the strongest benefit seen in vasculogenic ED [26]. Coverage for LiSWT is inconsistent and typically requires separate prior authorization as a medical procedure.

What to Tell Your Doctor to Maximize Coverage Approval

Your prescriber's documentation is the single biggest variable you control. Vague documentation ("patient wants Viagra") leads to automatic PA denials. Specific, guideline-aligned documentation gives your insurer far less room to deny.

Ask your physician to include in the PA request:

• The ICD-10-CM diagnosis code (N52.9 for unspecified ED, or a more specific subcode such as N52.01 for erectile dysfunction due to arterial insufficiency)
• Your IIEF-5 score, a validated five-question patient-reported outcome measure with scores below 21 indicating some degree of ED [27]
• Documentation of cardiovascular safety clearance, confirming no concurrent nitrate use and acceptable blood pressure at baseline
• Any comorbidities that make ED clinically significant, such as type 2 diabetes (which carries a 3-fold higher prevalence of ED than the general population [28]) or hypogonadism
• A statement that the requested drug is the prescriber's preferred agent given your clinical profile, and why a formulary alternative is clinically inferior for you specifically

Prescribers who submit PA requests with this level of detail have higher approval rates than those who submit minimal documentation. Your prescriber's office coordinator, or a specialty pharmacy affiliated with your provider, can often help prepare the PA submission.

Call 1-800-826-0940 (Network Health member services, commercial plans) or the number on the back of your insurance card to confirm your specific plan's PA criteria before your prescriber submits the request. Knowing the exact criteria in advance lets your physician tailor the documentation precisely, reducing back-and-forth and shortening the time to a decision.